[Metabolic changes induced with salmon calcitonin in post-menopausal osteoporosis].
10 patients suffering from post-menopausal osteoporosis were subjected to venous infusion of salmon calcitonine at a dose of 100 U.M.R.C. Essential inital biochemical data were hypocalcaemia associated with plasma increase in AMPc and, in the late phase, an increase in urinary excretion of phosphate and AMPc. In addition to conserving its physiological properties in osteoporotic disease also, the hormone is thus able to provoke a secondary secretion of parathormone. The use of CT in the treatment of post-menopausal osteoporosis is therefore recommended not only because of its evident action on bone reabsorption processes, which usually predominate in this dysmetabolic disease of the skeleton, but also in the indirect secretion of parathyroid hormone which is capable of positively affecting synthesis of 1-25 (OH)2 D3 and intestinal calcic absorption.
D000368:Aged; D002116:Calcitonin / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D000242:Cyclic AMP / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000378:metabolism; D010710:Phosphates / Q000652:urine
D010281:Parathyroid Hormone; D010710:Phosphates; D002116:Calcitonin; D000242:Cyclic AMP; D002118:Calcium
Modificazioni metaboliche indotte dalla calcitonina di salmone nella osteoporosi post-menopausale.